IST-3: A Major Contribution to Thrombolysis Research

1 Whiteley W. Lindley R. Wardlaw J. Sandercock P. Third international stroke trial. Int J Stroke 2006; 1:172–6.

2 The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352–63.

3 Wardlaw J.M. Murray V. Berge E. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379:2364–72.

4 Ma H. Parsons M.W. Christensen S. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate Extending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012; 7:74–80.

5 Parsons M. Spratt N. Bivard A. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366: 1099–107.

6 Fiebach J.B. Al-Rawi Y. Wintermark M. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012; 43:1561–6.

7 The Internet Stroke Center. 2012. Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED). Accessed 21 June 2012, 2012, at http://www.strokecenter.org/trials/clinicalstudies/enhanced-control-of-hypertension-and-thrombolysis-stroke-study-enchanted.